Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.06.19
Views: 854

Dr Joel Neal - Stanford University, Stanford, USA

Dr Joel Neal talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a study looking at the anti-tumour activity of oral investigational EGFR/HER2 inhibitor TAK-788 in NSCLC patients with EGFR exon 20 insertions.

He explains that EGFR mutant NSCLC with exon 20 insertions is a very particular type of the cancer.

It makes up only 5% of EGFR mutant lung cancer with EGFR mutant lung cancer making up just 15% of NSCLC.

Dr Neal explains that the data presented is mainly from one of the extension cohorts and that out of these patients a 43% response rate was seen, comparing favourably to other drugs in its class.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation